Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678892 | 1.00 | ESR1 (0.34) | ESR1ESR2CYP3A4CYP2C9TSHR | |
| SCHEMBL6683176 | 0.93 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL6683178 | 0.93 | ESR1 (0.31) | ESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL432351 | 0.86 | — | — | |
| SCHEMBL815076 | 0.86 | NOS1 (0.37) | NOS3NOS1NOS2 | |
| SCHEMBL5888802 | 0.85 | EPHX2 (0.31) | TSHR | |
| SCHEMBL15536154 | 0.83 | — | — | |
| Butadiene SCHEMBL3476348 | 0.80 | ESR1 (0.38) | ESR1ESR2CYP3A4CYP2C9TSHR | |
| SCHEMBL9556372 | 0.80 | ESR2 (0.38) | ESR2TSHR | |
| SCHEMBL9556377 | 0.80 | ESR2 (0.38) | ESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2247146-A | — | — | None | — | — | JP | disclosed |
| JP-7313177-A | — | — | None | — | — | JP | disclosed |
| JP-63006056-A | — | — | None | — | — | JP | disclosed |
| US-20110141418-A1 | LIQUID CRYSTAL COMPOUNDS | QINETIQ LIMITED (GB) | 2011-06-16 | — | — | US | disclosed |
| EP-1905597-B1 | Inkjet recording apparatus | FUJIFILM CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-7671191-B2 | Methods for preparing 2-alkynyladenosine derivatives | PGX HEALTH, LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADENOSINE THERAPEUTICS, LLC | 2008-07-24 | — | — | US | disclosed |
| EP-1905597-A2 | Inkjet recording apparatus | FUJIFILM Corporation (JP) | 2008-04-02 | — | — | EP | disclosed |
| JP-H07313177-A | PRODUCTION OF TRANS-CYCLOHEXYLMETHYL ESTER | ASAHI DENKA KOGYO KK | 1995-12-05 | — | — | JP | disclosed |
| US-5354502-A | Very large dielectric anisotropy and small birefringence | SEIKO EPSON CORPORATION (JP) | 1994-10-11 | — | — | US | disclosed |
| US-5238599-A | Low threshold voltage, low driving voltage | SEIKO EPSON CORPORATION (JP) | 1993-08-24 | — | — | US | disclosed |
| EP-0447565-A1 | 1,3-DIOXANE DERIVATIVE AND LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME | SEIKO EPSON CORPORATION (JP) | 1991-09-25 | — | — | EP | disclosed |
| EP-0400861-A1 | 1,3-dioxane derivative and liquid crystal composition incorporating the same | SEIKO EPSON CORPORATION (JP) | 1990-12-05 | — | — | EP | disclosed |
| JP-H02247146-A | TRICYCLIC COMPOUND HAVING OXYMETHYLENE BOND | DAINIPPON INK & CHEM INC | 1990-10-02 | — | — | JP | disclosed |
| JP-S636056-A | ANTHRAQUINONE DYE AND LIQUID CRYSTAL COMPOSITION CONTAINING SAME | NIPPON KANKO SHIKISO KENKYUSHO:KK | 1988-01-12 | — | — | JP | disclosed |
| EP-0058512-B1 | LIQUID CRYSTAL COMPOUNDS EXHIBITING A SMALL DIELECTRIC ANISOTROPY AND LIQUID CRYSTAL MATERIALS AND DEVICES INCORPORATING SUCH COMPOUNDS | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1986-01-15 | — | — | EP | disclosed |
| US-4556745-A | BICYCOL(2.2.2) OCATANE RING | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1985-12-03 | — | — | US | disclosed |
| US-4357078-A | ELECTROOPTICS; DISPLAYING | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1982-11-02 | — | — | US | disclosed |
| EP-0058512-A1 | Liquid crystal compounds exhibiting a small dielectric anisotropy and liquid crystal materials and devices incorporating such compounds | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110141418-A1 | LIQUID CRYSTAL COMPOUNDS | HTR3D, HTR3C, SFXN3 | ESR1 4503/4885ESR2 4461/4885CYP3A4 2396/4885 |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADORA2A, ADORA3, ADORA1 | ESR1 3087/4885ESR2 2823/4885CYP3A4 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.